24th April 2012

Response to denosumab for the treatment of bone metastases from solid tumours (ID 81)
ACD from the British Uro-oncology Group (BUG)

BUG welcomes the decision of the NICE panel on the role and use of denosumab in metastatic prostate cancer. Ensuring that patients across the country are benefitting from treatments that have been approved by NICE enables uniformity in patient care and this decision will assist with that. We are mindful that there are new treatments in metastatic prostate cancer that have shown improved survival and/or QOL and whilst these are not approved currently by NICE BUG takes this opportunity to thank the NICE panel for adopting a proactive approach as regards Bone Modifying Agents in prostate cancer. BUG would strongly support the feasibility of the other proven treatments to come on board for the benefit of this group of patients who hitherto had few treatment options.